These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Rationale for Immune Checkpoint Inhibitors Plus Targeted Therapy in Metastatic Melanoma: A Review. Dummer R; Ascierto PA; Nathan P; Robert C; Schadendorf D JAMA Oncol; 2020 Dec; 6(12):1957-1966. PubMed ID: 32970096 [TBL] [Abstract][Full Text] [Related]
49. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy. Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342 [TBL] [Abstract][Full Text] [Related]
50. New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy. Luke JJ; Ott PA Drug Healthc Patient Saf; 2014; 6():77-88. PubMed ID: 25018652 [TBL] [Abstract][Full Text] [Related]
51. Severe Colitis in 2 Patients with Melanoma Treated with BRAF/MEK Inhibitors: Case Report and Literature Review. Wautier C; Gourmaud J; Dong C; Berthod G Case Rep Oncol; 2024; 17(1):191-201. PubMed ID: 38312748 [TBL] [Abstract][Full Text] [Related]
52. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG. Franklin C; Mohr P; Bluhm L; Grimmelmann I; Gutzmer R; Meier F; Garzarolli M; Weichenthal M; Pfoehler C; Herbst R; Terheyden P; Utikal J; Ulrich J; Debus D; Haferkamp S; Kaatz M; Forschner A; Leiter U; Nashan D; Kreuter A; Sachse M; Welzel J; Heinzerling L; Meiss F; Weishaupt C; Gambichler T; Weyandt G; Dippel E; Schatton K; Celik E; Trommer M; Helfrich I; Roesch A; Zimmer L; Livingstone E; Schadendorf D; Horn S; Ugurel S J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688555 [TBL] [Abstract][Full Text] [Related]
53. Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma. Hermel DJ; Ott PA Cancer Metastasis Rev; 2017 Mar; 36(1):43-50. PubMed ID: 28181070 [TBL] [Abstract][Full Text] [Related]
54. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy? Kelley MC Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005 [TBL] [Abstract][Full Text] [Related]
55. The potential of BRAF-targeted therapy combined with immunotherapy in melanoma. Naderi-Azad S; Sullivan R Expert Rev Anticancer Ther; 2020 Feb; 20(2):131-136. PubMed ID: 32003263 [No Abstract] [Full Text] [Related]
56. Immunomodulatory effects of BRAF and MEK inhibitors: Implications for Melanoma therapy. Kuske M; Westphal D; Wehner R; Schmitz M; Beissert S; Praetorius C; Meier F Pharmacol Res; 2018 Oct; 136():151-159. PubMed ID: 30145328 [TBL] [Abstract][Full Text] [Related]
57. Immunotherapy in managing metastatic melanoma: which treatment when? Amaral T; Meraz-Torres F; Garbe C Expert Opin Biol Ther; 2017 Dec; 17(12):1523-1538. PubMed ID: 28891339 [TBL] [Abstract][Full Text] [Related]
58. The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era. Vanella V; Festino L; Trojaniello C; Vitale MG; Sorrentino A; Paone M; Ascierto PA Curr Oncol Rep; 2019 Jul; 21(9):76. PubMed ID: 31359162 [TBL] [Abstract][Full Text] [Related]
59. Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy-Paradoxical ERK Activation and Beyond. Jung T; Haist M; Kuske M; Grabbe S; Bros M Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576054 [TBL] [Abstract][Full Text] [Related]
60. The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma. Dimitriou F; Urner-Bloch U; Eggenschwiler C; Mitsakakis N; Mangana J; Dummer R; Urner M Eur J Cancer; 2021 Feb; 144():215-223. PubMed ID: 33373866 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]